A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

Summary

The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety.

Timeline

Start

2025-06-05

Primary completion

2027-07-14

Completion

2027-12-29

Drugs

Indications